Cloning and characterization of exodus, a novel beta-chemokine.

Robert Hromas, Patrick W. Gray(Walther Cancer Foundation), David Chantry(University Medical Center), Ronald Godiska(Walther Cancer Foundation), Mitchell D. Krathwohl(University Medical Center), Kenneth H. Fife(University Medical Center), Graeme I. Bell(Walther Cancer Foundation), Jun Takeda(Indiana University – Purdue University Indianapolis), Susan M. Aronica(Indiana University – Purdue University Indianapolis), Michael S. Gordon(Walther Cancer Foundation), Scott Cooper(Indiana University – Purdue University Indianapolis), Hal E. Broxmeyer(Walther Cancer Foundation), Michael J. Klemsz(University Medical Center)
PubMed
May 1, 1997
Cited by 172

Abstract

Chemokines are a family of related proteins that regulate leukocyte infiltration into inflamed tissue. Some chemokines such as MIP-1 alpha also inhibit hematopoietic progenitor cell proliferation. Recently, three chemokines, MIP-1 alpha, MIP-1 beta, and RANTES, have been found to significantly decrease human immunodeficiency virus production from infected T cells. We report here the cloning and characterization of a novel human chemokine termed Exodus for its chemotactic properties. This novel chemokine is distantly related to other chemokines (28% homology with MIP-1 alpha) and shares several biological activities. Exodus is expressed preferentially in lymphocytes and monocytes, and its expression is markedly upregulated by mediators of inflammation such as tumor necrosis factor or lipopolysaccharide. Purified synthetic Exodus was found to inhibit proliferation of myeloid progenitors in colony formation assays. Exodus also stimulated chemotaxis of peripheral blood mononuclear cells. The sequence homology, expression, and biological activity indicate that Exodus represents a novel divergent beta-chemokine.


Related Papers

No related papers found

Powered by citation graph analysis